featured
Sintilimab Plus Bevacizumab Biosimilar IBI305 and Chemotherapy for EGFR-Mutated Non-Squamous NSCLC After Progression on EGFR-TKI Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol 2022 Jul 28;[EPub Ahead of Print], S Lu, L Wu, H Jian, Y Chen, Q Wang, J Fang, Z Wang, Y Hu, M Sun, L Han, L Miao, C Ding, J Cui, B Li, Y Pan, X Li, F Ye, A Liu, K Wang, S Cang, H Zhou, X Sun, D Ferry, Y Lin, S Wang, W Zhang, C ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.